Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer

Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non‐small cell lung cancer. There are few reports describing bevacizumab‐induced chronic interstitial pneumonia. A 62‐year‐old man with advanced non‐small cell lung cancer was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekimoto, Yasuhito, Kato, Motoyasu, Shukuya, Takehiko, Koyama, Ryo, Nagaoka, Tetsutaro, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818583/
https://www.ncbi.nlm.nih.gov/pubmed/27081491
http://dx.doi.org/10.1002/rcr2.151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818583/
https://www.ncbi.nlm.nih.gov/pubmed/27081491
http://dx.doi.org/10.1002/rcr2.151

Ejemplares similares